Initial Results from a Phase 1 Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Subjects Followed for at Least 3 Months.

Details

Language :

English

ISSN :

00916749

Volume :

151

Issue :

2

Database :

Supplemental Index

Journal :

Journal of Allergy & Clinical Immunology

Publication Type :

Academic Journal

Accession number :

161727532

Full Text :

https://doi.org/10.1016/j.jaci.2022.12.426